Company / Profit Margin
Denali Therapeutics Inc. Profit Margin History
FY2020-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-43.9%
FY2023
5-year range
-740.7% / 21.2%
FY2020-FY2023
Trend
-307.4%
vs FY2022
Sector context
#89 of 145
Health Care
What the data says
Profit Margin changed -307% YoY in FY2023, a notable deviation from the 3-year average annual change of -915%.
Based on SEC 10-K filings.
-43.9% in FY2023 with a 3-year CAGR of -15.9%.
Improved from -740.7% to -43.9% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- -15.9pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#89 of 145 in Health CareTop 61% of 145This company -43.9% Sector average -792.7%
▼
+94.5% above sector average
Key checks
Key Insights
- In FY2023, profit margin decreased 307.4% year-over-year.
- Currently 748.7pp above the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | -43.9% | -307.4% |
| FY2022 | 21.2% | +102.9% |
| FY2021 | -740.7% | -2539.8% |
| FY2020 | -28.1% | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026